Semaglutide News and Research

Latest Semaglutide News and Research

New Year, new approach to weight loss: Almost three quarters of UK women are considering using GLP-1s in 2025

As 2024 draws to a close, the new year ushers in the opportunity to set new goals for the year ahead. While weight-loss and fitness are staples of New Year resolutions they are commonly known to be the unsustainable resolutions that don't continue past January.

3 Jan 2025

Lithocholic acid enhances health and lifespan, mimicking calorie restriction

Lithocholic acid (LCA), a metabolite induced by calorie restriction (CR), activates AMPK and mimics anti-aging benefits. A recent study highlights LCA's role in improving muscle performance, glucose tolerance, and lifespan in aged organisms.

1 Jan 2025

Study finds racial and ethnic disparities in the use of obesity-management drugs

Asians, non-Hispanic Blacks and Hispanics were significantly less likely than whites to use obesity-management medications to lower their weight compared with whites, new research suggests.

18 Dec 2024

Nutraceuticals: exploring potential benefits and challenges of an unregulated healthcare frontier

Nutraceuticals offer potential health benefits, from migraine relief to cognitive support, but safety and regulatory issues must be addressed for effective use.

18 Dec 2024

Danish studies find increased risk of optic nerve damage with diabetes medicine

Two independent studies from the University of Southern Denmark (SDU) show that patients with type 2 diabetes who are treated with the drug Ozempic have an increased risk of developing damage to the optic nerve of the eye, which can lead to severe and permanent loss of vision.

16 Dec 2024

Obesity prevalence and BMI decrease in the US for the first time in a decade

Obesity prevalence in the US decreased in 2023, with significant drops in the South, highlighting the impact of GLP-1RA medications on health trends.

16 Dec 2024

Revolutionizing MASLD treatment with GLP-1 receptor agonists

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic dysfunction-associated steatotic liver disease.

16 Dec 2024

The brain’s hunger switch: TRH neurons hold the key to obesity therapies

Scientists uncover how TRH neurons suppress hunger by inhibiting AgRP neurons, advancing our understanding of GLP-1-based obesity treatments.

9 Dec 2024

A reduction in BMI among adults is associated with lower health care spending, study suggests

A study reveals that weight loss can lead to significant healthcare savings, with 7% savings for a 5% BMI reduction and 30% for a 25% reduction in adults.

6 Dec 2024

Anti-obesity medications could help treat alcohol use disorders

Losing weight with anti-obesity medications (AOM) also resulted in decreased alcohol consumption for about half of the participants in a new study appearing in the current issue of JAMA Network Open.

4 Dec 2024

MIT engineers develop inflatable gastric balloon for weight loss

Gastric balloons - silicone balloons filled with air or saline and placed in the stomach - can help people lose weight by making them feel too full to overeat.

3 Dec 2024

Who gets obesity drugs covered by insurance? In North Carolina, it helps if you’re on Medicaid

After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets don't work.

2 Dec 2024

Nearly half of weight loss participants reduced alcohol use after starting anti-obesity medication

Researchers evaluate changes in alcohol use after initiating antiobesity medication.

29 Nov 2024

Expert explores the expanding applications of GLP1 therapies

Researchers review recent advancements in glucagon-like peptide-1-based therapies.

28 Nov 2024

Can fasting improve diabetes outcomes? Ramadan offers insights

A study during Ramadan shows intermittent fasting improves liver health, gut microbiota richness, and metabolic markers in T2DM patients. However, benefits fade quickly after fasting ends, highlighting the need for sustained interventions.

27 Nov 2024

GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

27 Nov 2024

Tirzepatide cuts diabetes risk by 90% in obese patients, study shows

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.

26 Nov 2024